Vaccine Adjuvants: Global Strategic Business Report

Global Vaccine Adjuvants Market to Reach $1.5 Billion by 2030

The global market for Vaccine Adjuvants estimated at US$735.7 Million in the year 2022, is projected to reach a revised size of US$1.5 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2022-2030. Particulate Adjuvants, one of the segments analyzed in the report, is projected to record 8.6% CAGR and reach US$513.1 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Adjuvant Emulsions segment is readjusted to a revised 8.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $218.7 Million, While China is Forecast to Grow at 8.4% CAGR

The Vaccine Adjuvants market in the U.S. is estimated at US$218.7 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$252.5 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8% and 7.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.

Select Competitors (Total 44 Featured) -

• Agenus, Inc.
• Avanti Polar Lipids, Inc.
• Brenntag Biosector A/S
• CSL Ltd.
• Invivogen
• Mvp Laboratories Inc.
• Novavax, Inc.
• OZ Biosciences SAS
• Seppic SA
• SPI Pharma

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and the publisher's Research Platform
• Complimentary updates for one year